Nurix Therapeutics COO Stefani A. Wolff resigns, effective May 2, 2023

Nurix Therapeutics, Inc.

Stefani A. Wolff notified resignation as COO and EVP of Product Development on April 5, 2023.
Departure effective May 2, 2023; no successor announced.
Wolff oversaw product development and operations; departure creates a senior management void.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stefani A. Wolff

Chief Operating Officer and Executive Vice President of Product Development

NRIX · Nurix Therapeutics, Inc.

Effective: 2023-05-02
Filed: April 10, 2023, 7:59 PM ET

On April 5, 2023, Stefani A. Wolff notified Nurix Therapeutics, Inc. (“Nurix”) of her decision to resign from her position as Chief Operating Officer and Executive Vice President of Product Development of Nurix, effective May 2, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Stefani A. Wolff resigned as Chief Operating Officer and Executive Vice President of Product Development at Nurix Therapeutics, Inc..

Action: resigned
Role: Chief Operating Officer and Executive Vice President of Product Development

Exact text from the filing

On April 5, 2023, Stefani A. Wolff notified Nurix Therapeutics, Inc. (“Nurix”) of her decision to resign from her position as Chief Operating Officer and Executive Vice President of Product Development of Nurix, effective May 2, 2023.

View on SEC.gov

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-095819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.